The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
A new type of non-opioid painkiller, aimed at treating short-term pain in adults, has been approved by the US Food and Drug ...
Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The Food and Drug Administration approved a new type of nonopioid painkiller, Journaxv, or suzetrigine, drugmaker Vertex ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration has approved JOURNAVX, an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor ...